IN2012DN02711A - - Google Patents
Download PDFInfo
- Publication number
- IN2012DN02711A IN2012DN02711A IN2711DEN2012A IN2012DN02711A IN 2012DN02711 A IN2012DN02711 A IN 2012DN02711A IN 2711DEN2012 A IN2711DEN2012 A IN 2711DEN2012A IN 2012DN02711 A IN2012DN02711 A IN 2012DN02711A
- Authority
- IN
- India
- Prior art keywords
- glucose
- animal
- amg
- gastrointestinal
- sglt
- Prior art date
Links
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 abstract 4
- 230000002496 gastric effect Effects 0.000 abstract 4
- 239000008103 glucose Substances 0.000 abstract 4
- HOVAGTYPODGVJG-ZFYZTMLRSA-N methyl alpha-D-glucopyranoside Chemical compound CO[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HOVAGTYPODGVJG-ZFYZTMLRSA-N 0.000 abstract 3
- 238000010521 absorption reaction Methods 0.000 abstract 2
- 230000000694 effects Effects 0.000 abstract 2
- 230000029142 excretion Effects 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 102000018711 Facilitative Glucose Transport Proteins Human genes 0.000 abstract 1
- 108091052347 Glucose transporter family Proteins 0.000 abstract 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 abstract 1
- 230000001419 dependent effect Effects 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 238000001727 in vivo Methods 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 210000003734 kidney Anatomy 0.000 abstract 1
- 229910052708 sodium Inorganic materials 0.000 abstract 1
- 239000011734 sodium Substances 0.000 abstract 1
- 229940121377 sodium-glucose co-transporter inhibitor Drugs 0.000 abstract 1
- 210000002700 urine Anatomy 0.000 abstract 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5082—Supracellular entities, e.g. tissue, organisms
- G01N33/5088—Supracellular entities, e.g. tissue, organisms of vertebrates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T436/00—Chemistry: analytical and immunological testing
- Y10T436/14—Heterocyclic carbon compound [i.e., O, S, N, Se, Te, as only ring hetero atom]
- Y10T436/142222—Hetero-O [e.g., ascorbic acid, etc.]
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Urology & Nephrology (AREA)
- Cell Biology (AREA)
- Pathology (AREA)
- Toxicology (AREA)
- General Health & Medical Sciences (AREA)
- Hematology (AREA)
- Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Endocrinology (AREA)
- Food Science & Technology (AREA)
- Biotechnology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- Tropical Medicine & Parasitology (AREA)
- General Physics & Mathematics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Microbiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Rheumatology (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Presented here are methods using alpha-methylglucoside (AMG) in vivo as an indicator for glucose absorption from the gastrointestinal (GI) system or glucose excretion in the urine after oral administration of AMG. The methods find use in, for example, but not limited to, determining the effect of a sodium-dependent glucose transporter (SGLT) inhibitor in an animal, comparing the differences in the effects of a first and second SGLT inhibitor in an animal, and diagnosing a disease associated with glucose absorption from the gastrointestinal (GI) system or glucose excretion from the kidney in an animal.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US24257009P | 2009-09-15 | 2009-09-15 | |
| PCT/US2010/048752 WO2011034846A1 (en) | 2009-09-15 | 2010-09-14 | Use of alpha-methylglucoside (amg) as an indicator for glucose absorption and excretion |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2012DN02711A true IN2012DN02711A (en) | 2015-09-11 |
Family
ID=42983318
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN2711DEN2012 IN2012DN02711A (en) | 2009-09-15 | 2010-09-14 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US8147801B2 (en) |
| EP (1) | EP2478357A1 (en) |
| JP (1) | JP5722901B2 (en) |
| CN (1) | CN102597770B (en) |
| AU (1) | AU2010295722B2 (en) |
| IN (1) | IN2012DN02711A (en) |
| WO (1) | WO2011034846A1 (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12115232B2 (en) * | 2017-11-21 | 2024-10-15 | Solvex Limited Liability Company | Preparation for magnetic resonance diagnostics for oncological diseases, comprising deuterated 3-O-methylglucose, and diagnostic method using said preparation |
| JP7570663B2 (en) | 2020-07-22 | 2024-10-22 | 国立大学法人群馬大学 | Novel diagnostic marker and novel therapeutic composition for diabetes, obesity and/or fatty liver |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2003254847B2 (en) | 2002-08-08 | 2009-06-04 | Kissei Pharmaceutical Co., Ltd. | Pyrazole derivative, medicinal composition containing the same, medicinal use thereof, and intermediate for production thereof |
| CN100351263C (en) * | 2002-08-08 | 2007-11-28 | 橘生药品工业株式会社 | Pyrazole derivative, medicinal composition containing the same, medicinal use thereof, and intermediate for production thereof |
| AU2003275713A1 (en) * | 2002-10-29 | 2004-05-25 | Takeda Pharmaceutical Company Limited | Use of sglt homolog |
| JP2005015460A (en) * | 2002-10-29 | 2005-01-20 | Takeda Chem Ind Ltd | Use of sglt homolog |
| JP2006521562A (en) * | 2003-03-07 | 2006-09-21 | スレショルド ファーマシューティカルズ インコーポレイティッド | Methods for determining tumor sensitivity to treatment with antineoplastic agents |
| NZ545304A (en) | 2003-08-01 | 2009-04-30 | Mitsubishi Tanabe Pharma Corp | Novel compounds having inhibitory activity against sodium-dependant transporter |
| AU2004261264A1 (en) * | 2003-08-01 | 2005-02-10 | Janssen Pharmaceutica N.V. | Substituted indazole-O-glucosides |
| JP2005139093A (en) * | 2003-11-05 | 2005-06-02 | Nichirei Corp | Glucose absorption inhibitor and method for producing the same |
| AR053329A1 (en) * | 2005-01-31 | 2007-05-02 | Tanabe Seiyaku Co | INDOL DERIVATIVES USEFUL AS INHIBITORS OF GLUCOSE CONVEYORS DEPENDENT ON SODIUM (SGLT) |
| TWI418556B (en) | 2006-07-27 | 2013-12-11 | Mitsubishi Tanabe Pharma Corp | Indole derivatives |
| TW200904454A (en) | 2007-03-22 | 2009-02-01 | Bristol Myers Squibb Co | Methods for treating obesity employing an SGLT2 inhibitor and compositions thereof |
| JP2009155212A (en) * | 2007-12-25 | 2009-07-16 | Taisho Pharmaceutical Co Ltd | Diabetes therapeutic agent comprising C-phenyl 1-thioglucitol compound as an active ingredient |
-
2010
- 2010-09-14 IN IN2711DEN2012 patent/IN2012DN02711A/en unknown
- 2010-09-14 US US12/881,695 patent/US8147801B2/en not_active Expired - Fee Related
- 2010-09-14 WO PCT/US2010/048752 patent/WO2011034846A1/en not_active Ceased
- 2010-09-14 EP EP10755292A patent/EP2478357A1/en not_active Withdrawn
- 2010-09-14 CN CN201080051671.0A patent/CN102597770B/en not_active Expired - Fee Related
- 2010-09-14 JP JP2012529847A patent/JP5722901B2/en not_active Expired - Fee Related
- 2010-09-14 AU AU2010295722A patent/AU2010295722B2/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| JP2013504769A (en) | 2013-02-07 |
| EP2478357A1 (en) | 2012-07-25 |
| WO2011034846A1 (en) | 2011-03-24 |
| AU2010295722B2 (en) | 2015-04-16 |
| US20110065200A1 (en) | 2011-03-17 |
| CN102597770B (en) | 2016-08-10 |
| CN102597770A (en) | 2012-07-18 |
| US8147801B2 (en) | 2012-04-03 |
| JP5722901B2 (en) | 2015-05-27 |
| AU2010295722A1 (en) | 2012-04-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112013010952A2 (en) | NMR systems and methods for rapid detection of analytes | |
| WO2011015602A3 (en) | Lung cancer biomarkers | |
| WO2010091049A3 (en) | Diagnosis and treatment of cancer | |
| WO2009085234A3 (en) | Use of micro-rna as a biomarker of immunomodulatory drug activity | |
| WO2009114603A3 (en) | Diffusion tensor imaging confidence analysis | |
| WO2010053587A3 (en) | Methods of monitoring conditions by sequence analysis | |
| WO2009025852A3 (en) | Methods of using mirna for detection of in vivo cell death | |
| MX2008014679A (en) | Assays for diagnosing and evaluating treatment options for fabry disease. | |
| ES2570632T3 (en) | In vitro leukocyte elastase inhibitor determination procedure for colorectal cancer | |
| EP4303584A3 (en) | Methods for detecting signatures of disease or conditions in bodily fluids | |
| ATE512681T1 (en) | DIALYSIS SYSTEM WITH NON-INVASIVE TEMPERATURE MEASUREMENT | |
| WO2008057437A3 (en) | Ex vivo flow cytometry method and device | |
| WO2008021290A3 (en) | Organ-specific proteins and methods of their use | |
| EP2209495A4 (en) | TAZ / WWTR1 FOR CANCER DIAGNOSIS AND TREATMENT | |
| FR2944019B1 (en) | METHOD FOR DETERMINING PRODEFENSIN-A6 FOR IN VITRO DIAGNOSIS OF COLORECTAL CANCER | |
| FR2919060B1 (en) | METHOD OF DETERMINING EZRINE FOR IN VITRO DIAGNOSIS OF COLORECTAL CANCER | |
| MX2010014228A (en) | METHODS AND PRODUCTS OF DIAGNOSIS OF THE P / GF-1 ACCOMPANYING. | |
| EP2585826A4 (en) | Methods and compositions for diagnosis and prognosis of renal injury and renal failure | |
| GB0711327D0 (en) | Diagnostic method | |
| WO2010028373A3 (en) | Methods for diagnosing cancer and determining the overall survival and disease-free survival of cancer patients | |
| WO2010033773A3 (en) | Diagnostic, prognostic and therapeutic uses of mirs in adaptive pathways and/or disease pathways | |
| WO2009114712A3 (en) | Assays for diagnosing and evaluating treatment options for pompe disease | |
| NZ592994A (en) | Diagnostic test for Streptococcus equi comprising assessing the presence or absence of the S. equi eqbE gene | |
| WO2012006056A3 (en) | Ccr6 as a biomarker of alzheimer's disease | |
| FR2904450B1 (en) | SENSOR SIMULATION SYSTEM. |